Porto PFX Biotech Today it has been announced that it has closed $ 2.5 million seed funds to advance its correct fermentation platform to produce the Biodentical Human Milk Protein-with the aim of providing durable, non-GMO and allergy-free nutrition solutions.
The round was led by EIT Food and Beta Capital as well as Buenvista Equity Partners. It matches the recent € 2.5 million grants from the EIC Accelerator, which allow PFX biotech to enhance lactopherin’s production at the pre-industry level, establish its own bispoke labs and increase the team.
“This is a defined moment for PFX Biotech“Said Ali OsmanFounder and CEO of PFX Biotech. “We are proud to be supported by missions – more sustainable nutrition model has been aligned to help unlock the feasibility of lactopherin. As we enter this new growth stage, we are actively searching strategic cooperation throughout research and development, scale-up and go-market opportunities.“
Established in 2022, PFX Biotech is developing an engineering biology platform to produce highly biochemical human milk protein through a scleble altar for use in advanced nutrition markets.
Their group brings the experience of dairy protein, gonna, molecular biology, scale up and open innovation, which is the root of stability.
The engineering biology-based platform of PFX Biotech can be made from child sources, sports nutrition and veteran nutrient products to consumer products for large size production of functional ingredients with human milk protein.
Human milk proteins are gold nutrients and health-promoting proteins in the nutrition of early life. The highly biomactory alternative produces human milk protein, through the right causes, PFX is creating a new division material that will support and enhance the prevention.
Beyond the new generation of children, their non-allergenic, GMO-, dairy-and animal-free proteins are easily digestable and organic available, they make the ideal for all populations with certain nutrients, such as elderly and athletes.
“Our trust“Said BB Sattar MarxBuenvista is a partner of the Equity Partners. “This investment reflects our confidence in the PFX team to lead our view in biology-powered solutions to re-shape the food system.“
At a time when appropriate gonna is derived as a basic technology for a durable, nutritious and elastic food system, this dual achievement keeps the PFX biotech in an ideal position to further its progress in this case.
“We are not only driven by the urgent need to take serious steps towards disrupting the current protein production system, but also enthusiastic about our aims to positively influence the lives of millions of people,“Added PFX BiotechThe
[publish_date
